The CEO of Nostrum Laboratories, a small, Missouri-based drug manufacturer, has defended his decision to raise the price of an antibiotic by more than $2,000. He reportedly called the markup a “moral requirement” and defended Martin Shkreli, saying the hedge-fund manager was acting in the best interests of shareholders. (Financial Times)

Acorda Therapeutics’ patents for MS drug Ampyra are not valid, a U.S. appeals court has ruled. The decision could allow a competitor to create a generic version of the drug, which is Acorda’s flagship treatment. (Reuters)

An Upstate New York fertility center is offering in vitro fertilization for about a third of the average national cost. The procedure is not typically covered by insurance. The clinic’s staff says it is possible for the model — high-volume, low-cost fertility treatments — to work elsewhere. (Wall Street Journal)

Intellectual property rights for CRISPR-Cas9 gene editing belong to the Broad Institute of MIT and Harvard, the U.S. Court of Appeals for the Federal Circuit has ruled. The decision has brought to an end a years-long patent battle between the universities and a team of researchers at the University of California, Berkeley. (Nature)

The strength of Amgen’s data on its double-sided antibody therapy for multiple myeloma could pose a risk for Celgene and Bluebird Bio, which are developing CAR-T treatments for the cancer. The antibody therapy is said to be easier to make and administer. (STAT)